Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice

Cancer Research

Volumn 59, Issue 14, 1999, Pages 3396-3403

  Gnant, Michael F X ^a,b   Puhlmann, Markus ^a,c   Alexander Jr , H Richard ^a   Bartlett, David L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; LUCIFERASE;

ANIMAL CELL; ARTICLE; CANCER SURVIVAL; COLON CARCINOMA; CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; CYTOSINE DEAMINASE; FEMALE; FLUCYTOSINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEOSIDE DEAMINASES; PRODRUGS; RECOMBINANT FUSION PROTEINS; VACCINIA VIRUS;

EID: 0033565215     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Steele, G., Jr., Bleday, R., Mayer, R. J., Lindblad, A., Petrelli, N., and Weaver, D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: gastrointestinal tumor study group protocol 6584. J. Clin. Oncol., 9: 1105-1112, 1991.
2. Advanced Colorectal Cancer Meta-Analysis Project - no authors listed. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
3. Huber, B. E., Richards, C. A., and Austin, E. A. Virus-directed enzyme/prodrug therapy (VDEPT). Ann. NY Acad. Sci., 716: 104-114, 1994.
4. Moolten, F. L. An alternative to the magic bullet paradigm for specific cancer therapy. Med. Hypotheses, 24: 43-51, 1987.
5. Moolten, F. L., Wells, J. M., Heyman, R. A., and Evans, R. M. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum. Gene Ther., 1: 125-134, 1990.
6. Martin, L. A., Vile, R., Lemoine, N. R., Sikora, K., and Pandha, H. S. Genetic prodrug activation therapy. Lancet, 350: 1793-1794, 1997.
7. Zhang, J., and Russell, S. J. Vectors for cancer gene therapy. Cancer Metastasis Rev., 15: 385-401, 1996.
8. Dachs, G. U., Dougherty, G. J., Stratford, I. J., and Chaplin, D. J. Targeting gene therapy to cancer: a review. Oncol. Res., 9: 313-325, 1997.
9. Singhal, S., and Kaiser, L. R. Cancer chemotherapy using suicide genes. Surg. Oncol. Clin. North Am., 7: 505-536, 1998.
10. Jolly, D. Viral vector systems for gene therapy. Cancer Gene Ther., 1: 51-64, 1994.
11. Kianmanesh, A. R., Perrin, H., Panis, Y., Fabre, M., Nagy, H. J., Houssin, D., and Klatzmann, D. A. "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum. Gene Ther., 8: 1807-1814, 1997.
12. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
13. Huber, B. E., Richards, C. A., and Krenitsky, T. A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA, 15: 8039-8043, 1991.
14. Mroz, P. J., and Moolten, F. L. Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum Gene Ther, 4: 589-595, 1993.
15. Parker, W. B., King, S. A., Allan, P. W., Bennett, L. L., Jr., Secrist, J. A., Montgomery, J. A., Gilbert, K. W., Waud, W. R., Wells, A. H., Gillespie, G. Y., and Sorscher, E. J. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum. Gene Ther., 8: 1637-1644, 1997.
16. Mullen, C. A., Kilstrup, M., and Blaese, R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33-37, 1992.
17. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.
18. Hoganson, D. K., Batra, R. K., Olsen, J. C., and Boucher, R. C. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res., 56: 1315-1323, 1996.
19. Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T., and Good, S. S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA, 91: 8302-8306, 1994.
20. Trinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C., and Huber, B. E. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res., 55: 4808-4812, 1995.
21. Hirschowitz, E. A., Ohwada, A., Pascal, W. R., Russi, T. J., and Crystal, R. G. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum. Gene Ther., 6: 1055-0163, 1995.
22. Puhlmann, M., Brown, C. K., Gnant, M., Huang, J., Libutti, S. K., Alexander, H. R., and Bartlett, D. L. Vaccinia as a vector for tumor directed gene therapy: biodistribution of a thymidine kinase deleted mutant. Cancer Gene Ther., in press, 1999.
23. Chakrabarti, S., Sisler, J. R., and Moss, B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques, 23: 1094-1097, 1997.
24. Falkner, F. G., and Moss, B. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J. Virol., 62: 1849-1854, 1988.
25. Yuen, L., and Moss, B. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc. Natl. Acad. Sci. USA, 84: 6417-6421, 1987.
26. Davison, A. J., and Moss, B. Structure of vaccinia virus early promoters. J. Mol. Biol., 210: 749-769, 1989.
27. Davison, A. J., and Moss, B. Structure of vaccinia virus late promoters. J. Mol. Biol., 210: 771-784, 1989.
28. Earl, P. L., and Moss, B. Current protocols in molecular biology. In: F. M. Ausubel, R. Kinston, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith and K. Struhl (eds.), Current Protocols in Molecular Biology, pp. 16.15.1-16.18.10. New York: Greene/Wiley Interscience, 1991.
29. Corbett, T. H., Griswold, D. P., and Roberts, B. J. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res., 35: 2434-2439, 1975.
30. Tsung, K., Yim, J. H., Mari, W., Buller, R. M. L., and Norton, J. A. Gene Expression and Cytopathic Effect of Chemically Inactivated Vaccinia Virus. J. Virol., 70: 165-171, 1996.
31. Lafreniere, G., and Rosenberg, S. A. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J. Natl. Cancer Inst., 76: 309-322, 1986.
32. Kaplan, E. L., and Meier, P. Non-parametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
33. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep, 50: 163-170, 1966.
34. Brand, K., Arnold, W., Bartels, T., Lieber, A., Kay, M. A., Strauss, M., and Dorken, B. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther., 4: 9-16, 1997.
35. Vile, R. G., Nelson, J. A., Castleden, S., Chong, H., and Hart, I. R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res., 54: 6228-6234, 1994.
36. Liang, X., Hartikka, J., Sukhuy, L., Manthorpe, M., and Hobart, P. Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy. Gene Ther., 3: 350-356, 1996.
37. Blackburn, R. V., Galoforo, S. S., Corry, P. M., and Lee, Y. J. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res., 58: 1358-1362, 1998.
38. Peplinski, G. R., Tsung, K., Whitman, E. D., Meko, J. B., and Norton, J. A. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1β. Ann. Surg. Oncol., 2: 151-159, 1995.
39. Peplinski, G. R., Tsung, K., Meko, J. B., and Norton, J. A. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1β. Surgery (St. Louis), 118: 185-191, 1995.
40. Buller, R. M., Smith, G. L., Cremer, K., Notkins, A. L., and Moss, B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature (Lond.), 317: 813-815, 1985.
41. Peplinski, G. R., Tsung, K., and Norton, J. A. Vaccinia virus for human gene therapy. Surg. Oncol. Clin. N. Am., 7: 575-588, 1998.
42. Qin, H., and Chatterjee, S. K. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum. Gene Ther., 7: 1853-1860, 1996.
43. Meko, J. B., Yim, J. H., Tsung, K., and Norton, J. A. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res., 55: 4765-4770, 1995.
44. McAneny, D., Ryan, C. A., Beazley, R. M., and Kaufman, H. L. Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann. Surg. Oncol., 3: 495-500, 1996.
45. Bronte, V., Carroll, M. W., Goletz, T. J., Wang, M., Overwijk, W. W., Marincola, F., Rosenberg, S. A., Moss, B., and Restifo, N. P. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA, 94: 3183-3188, 1997.
46. Hodge, J. W., Abrams, S., Schlom, KJ., and Kantor, J. A. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res., 54: 5552-5555, 1994.
47. Peplinski, G. R., Tsung, K., Meko, J. B., and Norton, J. A. Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses. Ann. Surg. Oncol., 31: 15-23, 1996.
48. Moss, B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci., USA, 93: 11341-11348, 1996.
49. Paoletti, E. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA, 93: 11349-11353, 1996.
50. Kim, C. J., Cormier, J., Roden, M., Gritz, L., Mazzara, G. P., Fetsch, P., Hijazi, Y., Lee, K. H., Rosenberg, S. A., and Marincola, F. M. Use of recombinant poxviruses to stimulate anti-melanoma T-cell reactivity. Ann. Surg. Oncol., 5: 64-76, 1998.
51. Cooney, E. L., Collier, A. C., Greenberg, P. D., Coombs, R. W., Zarling, J., Arditti, D. E., Hoffman, M. C., Hu, S. L., and Corey, L. Safety of an immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet, 337: 567-572, 1991.
52. de Roos, W. K., Fallaux, F. J., Marinelli, A. W. K. S., Lazaris-Laratzas, A., von Geusau, B. A., Van Der Eb, M. M., Cramer, S. J., Terpstra, O. T., and Hoeben, R. C. Isolated-organ perfusion for local gene delivery: efficient adenovirus-mediated gene transfer into the liver. Gene Ther., 4: 55-62, 1997.
53. Ju, D. W., Cao, X., and Acres, B. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model. Cancer Gene Ther., 4: 139-144, 1997.
54. Rosenberg, S. A. Gene therapy for cancer. J. Am. Med. Assoc., 268: 2416-2419, 1992.
55. Topf, N., Worgall, S., Hackett, N. R., and Crystal, R. G. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther., 5: 507-513, 1998.
56. Van Der Eb, M. M., Cramer, S. J., Vergouwe, Y., Schagen, F. H. E., van Krieken, J. H. J. M., van der Eb, A. J., Rinkes, I. H. M. B., Van de Velde, C. J. H., and Hoeben, R. C. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther., 5: 451-458, 1998.
57. Kwong, Y-L., Chen, S-H., Kosai, K., Finegold, M. J., and Woo, S. L. C. Adenoviral-mediated suicide gene therapy for hepatic metastases of breast cancer. Cancer Gene Ther., 3: 339-344, 1996.
58. Caruso, M., Panis, Y., Gagandeep, S., and Houssin, D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA, 90: 7024-7028, 1993.
59. Consalvo, M., Mullen, C. A., Modesti, A., Musiani, P., Allione, A., Cavallo, F., Giovarelli, M., and Forni, G. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J. Immunol., 154: 5302-5312, 1995.